首页> 外文期刊>Терапевтичесκий архив >Arterial hypertension in chronic glomerulonephritis: detectability and treatment efficacy
【24h】

Arterial hypertension in chronic glomerulonephritis: detectability and treatment efficacy

机译:慢性肾小球肾炎的动脉高血压:可检测性和治疗效果

获取原文
获取原文并翻译 | 示例
       

摘要

AIM: To study prevalence of arterial hypertension (AH) in patients with chronic glomerulonephritis (CGN), its relationship with activity of the renal process, renal function; to analyse policy and efficacy of antihypertensive therapy. MATERIAL AND METHODS A total of 250 CGN patients treated in 1993-2001 participated in the trial. They had different morphological variants of CGN. AH was diagnosed in 193 patients. In the course of the trial changes in antihypertensive treatment policy were observed. RESULTS: AH was most prevalent in mesangiocapillary (96.6%) and diffuse fibroplastic nephritis (83.9%). In functional insufficiency of the kidneys AH occurred in 90.1%. AH was associated with clinical and morphological signs of nephritis activity, severity of tubulointerstitial alterations, purin and lipid metabolism. Uric acid level and age were independent prognostic factors of AH development. AH correction was achieved in the initial and subsequent periods in 51.7 and 58.7% cases. Later, ACE inhibitors were prescribed more often, both in monotherapy and in combination with other drugs; calcium antagonists were taken less frequently. CONCLUSION: AH in CGN patients is a frequent finding and depends on a morphological nephritis variant, activity of the renal process and degree of renal failure. Age, gender and metabolic disorders are also involved in AH development in CGN patients. Recently, there is a trend to more frequent prescription of combined treatment. Drugs of choice in the treatment of renal AH are ACE inhibitors.
机译:目的:研究慢性肾小球肾炎(CGN)患者的动脉高压(AH)患病率及其与肾脏活动,肾功能的关系;分析抗高血压治疗的政策和疗效。材料与方法在1993年至2001年期间,共治疗了250名CGN患者。它们具有不同的CGN形态变异。 193例患者被确诊为AH。在试验过程中,观察到抗高血压治疗政策的变化。结果:AH在血管毛细血管(96.6%)和弥漫性纤维增生性肾炎(83.9%)中最普遍。在肾功能不全中,AH发生率为90.1%。 AH与肾炎活动,肾小管间质改变的严重程度,嘌呤和脂质代谢的临床和形态学征象有关。尿酸水平和年龄是AH发展的独立预后因素。在初期和后续阶段,分别有51.7和58.7%的患者实现了AH矫正。后来,无论是单一疗法还是与其他药物联合使用,ACE抑制剂的使用频率都更高。钙拮抗剂的服用频率较低。结论:CGN患者的AH是一种常见的发现,并取决于形态学上的肾炎变体,肾过程的活动性和肾功能衰竭的程度。年龄,性别和代谢紊乱也与CGN患者的AH发展有关。最近,有一种趋势是更频繁地开出联合治疗处方。治疗肾AH的首选药物是ACE抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号